Cribstone Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cribstone Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4	Closed	–	–	467
2022 Q1	$0	Buy	+4	New	+$335	﹤0.01%	419
2020 Q1	–	Sell	-52	Closed	-$4K	–	348
2019 Q4	$4K	Hold	52	–	–	﹤0.01%	314
2019 Q3	$4K	Hold	52	–	–	﹤0.01%	495
2019 Q2	$4K	Hold	52	–	–	﹤0.01%	528
2019 Q1	$5K	Hold	52	–	–	﹤0.01%	538
2018 Q4	$4K	Hold	52	–	–	﹤0.01%	591
2018 Q3	$5K	Hold	52	–	–	﹤0.01%	603
2018 Q2	$5K	Hold	52	–	–	﹤0.01%	604
2018 Q1	$4K	Hold	52	–	–	﹤0.01%	624
2017 Q4	$5K	Buy	+52	New	+$4.52K	﹤0.01%	660

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cribstone Capital Management's BMRN Position: Q2 2022 in Review

Cribstone Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 4 shares.

Cribstone Capital Management first reported a position in BMRN in Q4 2017 and held it in 10 quarters. The position peaked at $5K in Q1 2019. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Cribstone Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Cribstone Capital Management sold 4 BioMarin Pharmaceuticals shares in Q2 2022.
Cribstone Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 10 quarters.
Cribstone Capital Management's BioMarin Pharmaceuticals position peaked at $5K in Q1 2019.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Cribstone Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.